查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612623

血流感染检测市场：依产品类型、技术和最终用途划分－2025-2030 年全球预测

Bloodstream Infection Testing Market by Product (Instruments, Reagents & Consumables), Sample Type (Blood Culture, Whole Blood), Technology, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

血流感染检测市场2023年估值为11.2亿美元，预计到2024年将达到12亿美元，复合年增长率为7.64%，到2030年将达到18.8亿美元。

血流感染 (BSI) 检测在诊断进入血液的感染疾病发挥重要作用，这种感染可能导致败血症等严重。此类检测的范围包括多种方法，包括传统的血液培养技术和旨在快速识别病原体的先进分子检测技术。这些测试对于及时诊断至关重要，这对于有效的患者管理和治疗至关重要。典型应用包括医院、诊断实验室和专业临床环境，用于检测细菌、真菌和病毒病原体。最终用途领域广泛，包括医疗机构、研究机构和专注于开发新型治疗策略的製药公司。

主要市场统计
基准年[2023] 11.2亿美元
预计年份 [2024] 12亿美元
预测年份 [2030] 18.8亿美元
复合年增长率（%） 7.64%

血流感染检测市场的成长是由医院感染数量增加、人口老化加剧以及诊断技术进步等因素所推动的。此外，对快速结果的需求不断增长，刺激了自动化就地检验设备的采用。特别是在医疗保健服务和基础设施不断扩大的新兴市场，快速、经济高效且高度敏感的诊断工具的开发和商业化存在潜在的商机。公司应专注于与生物技术公司合作开发和分销套件，以最大限度地提高市场渗透率。

然而，他们面临先进测试工具成本高昂、部分地区报销场景有限等挑战。此外，某些诊断测试的复杂性可能会阻碍其在资源匮乏的环境中的广泛使用。新技术的发展可以集中在提高分子诊断工具的准确性和速度，以及开发价格实惠的便携式检测套组。优先研究奈米技术和微流体有可能产生创新的诊断解决方案并促进广泛使用。市场竞争激烈，技术日新月异，需要不断研究与适应。企业应寻求协同效应合作并投资于前沿研究，以保持竞争力并有效解决未满足的需求。

市场动态：揭示快速发展的血流感染检测市场的关键市场洞察

供需的动态交互作用正在改变血流感染检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球血流感染疾病呈上升趋势
    • 倾向于利用基于血液的诊断策略
    • 政府努力提高人们对血液相关疾病的认识并改善血液安全
  • 市场限制因素
    • 报销政策复杂且保险范围不足
  • 市场机会
    • 开发新血液检测、基于血液的抗生素检测和次世代定序仪的研究活动
    • 采用人工智慧、机器学习技术和新生物标记进行血流感染检测
  • 市场挑战
    • 血流感染检测的技术和临床局限性以及污染的可能性

波特五力：驾驭血流感染检测市场的策略工具

波特的五力框架是了解血流感染检测市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血流感染检测市场的外部影响

外部宏观环境因素在塑造血流感染检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解血流感染检测市场的竞争状况

对血流感染测试市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵血流感染检测市场供应商绩效评估

FPNV定位矩阵是评估血流感染检测市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，绘製血流感染检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对血流感染检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的血流感染疾病呈上升趋势
      • 使用基于血液的诊断策略的趋势
      • 政府旨在提高人们对血液相关疾病的认识并改善血液安全的倡议
    • 抑制因素
      • 报销政策复杂且保险范围不足
    • 机会
      • 旨在开发新的血液检测、基于血液的抗菌检测和次世代定序的研究活动
      • 采用人工智慧、机器学习技术和新生物标记进行血流感染检测
    • 任务
      • 血流感染检测的技术和临床局限性以及污染的可能性
  • 市场区隔分析
    • 产品：探索血流感染检测设备以获得快速可靠的检测结果
    • 最终用途：诊断中心的多功能用途，以实现高效测试
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章血流感染检测市场：副产品

  • 装置
  • 试剂/耗材

第七章依样本类型分類的血流感染检测市场

  • 血液培养
  • 全血

第八章血流感染检测市场：依技术分类

  • 原位杂交
  • 质谱分析
  • PCR

第九章血流感染检测市场：依最终用途分类

  • 学术研究所
  • 诊断中心
  • 医院

第十章美洲血流感染检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太血流感染检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲的血流感染检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 将血液检测和人工智慧结合，实现败血症管理中的高阶诊断、早期检测和风险评估
    • 战略伙伴关係加强了波兰对血流感染疾病和败血症的诊断
    • Oxford Nanopore 与 Day Zero Diagnostics 之间的创新合作，用于快速血流感染疾病诊断
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Advacare Pharma
  • Bactiguard AB
  • Becton, Dickinson and Company
  • BioMerieux
  • Bruker Corporation
  • Cardinal Health
  • Cepheid
  • CorMedix Inc.
  • Diasorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fresenius Medical Care AG & Co. KGaA
  • HiMedia Laboratories Pvt. Ltd
  • ITL Health Group
  • Johnson & Johnson Services, Inc
  • Kurin Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Holdings A/S
  • Pfizer Inc.
  • Pro-Lab Diagnostics
  • Sanofi SA
  • Sepsis Alliance
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4D00F1312BD4

The Bloodstream Infection Testing Market was valued at USD 1.12 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 7.64%, to USD 1.88 billion by 2030.

Bloodstream infection (BSI) testing plays a vital role in diagnosing infections that enter the bloodstream, potentially leading to serious conditions like sepsis. The scope of such testing encompasses various methods, including traditional blood culture techniques and advanced molecular testing technologies, designed to identify pathogens rapidly. These tests are essential for timely diagnosis, which is crucial for effective patient management and treatment. The primary applications extend across hospitals, diagnostic laboratories, and specialized clinical settings, where they are used to detect bacterial, fungal, or viral pathogens. End-use sectors range widely, covering healthcare facilities, research institutions, and pharmaceutical companies that focus on developing novel therapeutic strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 1.12 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 1.88 billion
CAGR (%) 7.64%

Market growth in bloodstream infection testing is driven by factors such as the increasing prevalence of hospital-acquired infections, the growing aging population, and advancements in diagnostic technologies. Furthermore, the rising demand for speedy results has fueled the adoption of automated and point-of-care testing devices. Potential opportunities lie in the development and commercialization of rapid, cost-effective, and highly sensitive diagnostic tools, especially in emerging markets where healthcare access and infrastructure are expanding. Companies should focus on partnerships and collaborations with biotech firms for kit development and distribution to maximize market penetration.

However, the market faces challenges such as high costs of advanced testing tools and limited reimbursement scenarios in some regions. Additionally, the complexity of certain diagnostic tests can hinder widespread adoption in lower-resource settings. Emerging innovations could focus on enhancing the accuracy and speed of molecular diagnostic tools and developing affordable, portable testing kits. Prioritizing research in nanotechnology and microfluidics could yield transformative diagnostic solutions, facilitating broad accessibility. The market is characterized by high competition with rapid technological turnover, necessitating continuous research and adaptation. Enterprises should look to synergistic collaborations and invest in cutting-edge research to maintain a competitive edge and address unmet clinical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bloodstream Infection Testing Market

The Bloodstream Infection Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of bloodstream infections across the world
    • Inclination towards utilization of blood-based diagnostics strategies
    • Government initiatives to raise awareness about blood-related diseases and improve blood safety
  • Market Restraints
    • Complex reimbursement policies and inadequate insurance coverage
  • Market Opportunities
    • Research activities to develop novel blood tests, blood-based antimicrobial tests, and next-generation sequencing
    • Adoption of AI, ML technologies, and new biomarkers for bloodstream infection testing
  • Market Challenges
    • Technical and clinical limitations of bloodstream infection testing and chances of contamination

Porter's Five Forces: A Strategic Tool for Navigating the Bloodstream Infection Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bloodstream Infection Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bloodstream Infection Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bloodstream Infection Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bloodstream Infection Testing Market

A detailed market share analysis in the Bloodstream Infection Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bloodstream Infection Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bloodstream Infection Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bloodstream Infection Testing Market

A strategic analysis of the Bloodstream Infection Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bloodstream Infection Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., Advacare Pharma, Bactiguard AB, Becton, Dickinson and Company, BioMerieux, Bruker Corporation, Cardinal Health, Cepheid, CorMedix Inc., Diasorin S.p.A., F. Hoffmann-La Roche Ltd, Fresenius Medical Care AG & Co. KGaA, HiMedia Laboratories Pvt. Ltd, ITL Health Group, Johnson & Johnson Services, Inc, Kurin Inc., Merck & Co., Inc., Novartis AG, Novo Holdings A/S, Pfizer Inc., Pro-Lab Diagnostics, Sanofi S.A., Sepsis Alliance, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bloodstream Infection Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments and Reagents & Consumables.
  • Based on Sample Type, market is studied across Blood Culture and Whole Blood.
  • Based on Technology, market is studied across In Situ Hybridization, Mass Spectroscopy, and PCR.
  • Based on End-use, market is studied across Academic & Research Institutes, Diagnostic Centers, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of bloodstream infections across the world
      • 5.1.1.2. Inclination towards utilization of blood-based diagnostics strategies
      • 5.1.1.3. Government initiatives to raise awareness about blood-related diseases and improve blood safety
    • 5.1.2. Restraints
      • 5.1.2.1. Complex reimbursement policies and inadequate insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Research activities to develop novel blood tests, blood-based antimicrobial tests, and next-generation sequencing
      • 5.1.3.2. Adoption of AI, ML technologies, and new biomarkers for bloodstream infection testing
    • 5.1.4. Challenges
      • 5.1.4.1. Technical and clinical limitations of bloodstream infection testing and chances of contamination
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Exploring bloodstream infection testing instruments for rapid and reliable test results
    • 5.2.2. End-use: Diverse scope of applications in diagnostic centers for efficient testing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bloodstream Infection Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables

7. Bloodstream Infection Testing Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Blood Culture
  • 7.3. Whole Blood

8. Bloodstream Infection Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. In Situ Hybridization
  • 8.3. Mass Spectroscopy
  • 8.4. PCR

9. Bloodstream Infection Testing Market, by End-use

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Diagnostic Centers
  • 9.4. Hospitals

10. Americas Bloodstream Infection Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bloodstream Infection Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bloodstream Infection Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Advanced Diagnostics in Sepsis Management, Integrating Blood Testing and AI for Early Detection and Risk Assessment
    • 13.3.2. Strategic Partnership Enhances Bloodstream Infection and Sepsis Diagnostics in Poland
    • 13.3.3. Innovative Collaboration for Rapid Bloodstream Infection Diagnostics, Oxford Nanopore and Day Zero Diagnostics Join Forces
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accelerate Diagnostics, Inc.
  • 3. Advacare Pharma
  • 4. Bactiguard AB
  • 5. Becton, Dickinson and Company
  • 6. BioMerieux
  • 7. Bruker Corporation
  • 8. Cardinal Health
  • 9. Cepheid
  • 10. CorMedix Inc.
  • 11. Diasorin S.p.A.
  • 12. F. Hoffmann-La Roche Ltd
  • 13. Fresenius Medical Care AG & Co. KGaA
  • 14. HiMedia Laboratories Pvt. Ltd
  • 15. ITL Health Group
  • 16. Johnson & Johnson Services, Inc
  • 17. Kurin Inc.
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Novo Holdings A/S
  • 21. Pfizer Inc.
  • 22. Pro-Lab Diagnostics
  • 23. Sanofi S.A.
  • 24. Sepsis Alliance
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BLOODSTREAM INFECTION TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. BLOODSTREAM INFECTION TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLOODSTREAM INFECTION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLOODSTREAM INFECTION TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 189. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2023